Aktis Oncology vs ResMed
Side-by-side comparison of AI visibility scores, market position, and capabilities
Clinical-stage oncology company completed $318M IPO in Jan 2026 — first biotech IPO of 2026 (Nasdaq: AKTS); Eli Lilly took $100M stake; developing alpha-emitting radiopharmaceutical AKY-1189 targeting Nectin-4 for bladder and other solid tumors.
About
Aktis Oncology is a Boston-based clinical-stage oncology company developing alpha-emitting radiopharmaceuticals against prevalent solid tumors. The company completed a $318 million IPO in January 2026 — the first significant biotech IPO of 2026 — pricing 17.65 million shares at $18 each on the Nasdaq under ticker AKTS. Eli Lilly stepped in to purchase $100 million of the offering.
ResMed (RMD) reported ~$4.7B revenue in FY2024. Global leader in cloud-connected devices for sleep apnea, COPD, and out-of-hospital care, with 10M+ connected devices. HQ: San Diego.
About
ResMed Inc. is the global leader in cloud-connected medical devices and software for diagnosing and treating sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions in out-of-hospital settings. Founded in Sydney, Australia in 1989, the company designs and manufactures CPAP (continuous positive airway pressure) machines, masks, ventilators, and related accessories used by patients with obstructive sleep apnea — a condition affecting approximately 1 billion people globally that is chronically under-diagnosed and under-treated.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.